article thumbnail

Taiwan Semiconductor Feels Confident About Its Long-Term Prospects

The Motley Fool

Fool.com contributor Parkev Tatevosian highlights why Taiwan Semiconductor Manufacturing (NYSE: TSM) feels so strongly about its growth prospects. Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month.

Prospects 130
article thumbnail

Forget Aurora Cannabis: 1 Cannabis Stock With Far Better Prospects

The Motley Fool

But when it comes to having "far better prospects" than Aurora Cannabis, which hasn't yet definitively proven it can turn a profit, I'd say that Green Thumb -- which has proven this -- probably fits that bill. The wild card: Legalization Final point: For investors who aren't yet entirely convinced that the U.S. national level.

Prospects 189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite

The Motley Fool

Some investors thought GLP-1 medicines such as Ozempic could decrease demand for some of Abbott's key products. Abbott's prospects remain strong Abbott Laboratories has an excellent track record of developing innovative medical devices. Here's the bottom line: Abbott Laboratories is still a top pick for long-term investors.

Prospects 130
article thumbnail

SoundHound AI Is Optimistic About Its Long-Term Prospects to 2025 and Beyond

The Motley Fool

Fool.com contributor Parkev Tatevosian elaborates on SoundHound AI 's (NASDAQ: SOUN) longer-term prospects. Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and SoundHound AI wasn’t one of them.

Prospects 130
article thumbnail

Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?

The Motley Fool

Could this news hurt Vertex's prospects in the billion-dollar pain market? All of this means Vertex investors shouldn't worry about the big biotech 's prospects in the billion-dollar pain market. Latigo Biotherapeutics recently scored $135 million in Series A financing to help it bring its candidate through phase 1 trials.

Prospects 130
article thumbnail

ASML Management Is Bullish on Its Long-Term Prospects

The Motley Fool

Before you buy stock in ASML, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ASML wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Prospects 130
article thumbnail

Great News for AMD Stock Investors

The Motley Fool

Fool.com contributor Parkev Tatevosian evaluates AMD 's (NASDAQ: AMD) prospects in the personal computing industry. Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month.

Investors 130